Drug intelligence / Profile preview

COVID-19 S-Vax-loaded autologous dendritic cell injection

Development stage: Unknown
Lead developer: Shanghai Juncell Therapeutics
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

COVID-19 S-Vax-loaded autologous dendritic cell injection is an investigational autologous dendritic cell vaccine developed by Beijing TIL Therapeutics for the prevention of COVID-19. The vaccine consists of ex vivo expanded monocyte-derived autologous dendritic cells loaded with COVID-19 S-Vax, a recombinant SARS-CoV-2 spike protein antigen. Upon subcutaneous administration, these antigen-loaded dendritic cells present the SARS-CoV-2 spike antigen to the host's immune system, priming CD4+ T helper cells and CD8+ cytotoxic T lymphocytes, and orchestrating the activation of B cells to elicit a robust protective immune response against SARS-CoV-2 infection.

Other names: autologous dendritic cell vaccine (Beijing TIL Therapeutics)COVID-19 S-Vax-loaded autologous dendritic cell therapyCOVID19 S-Vax-loaded autologous dendritic cell therapyCOVID 19 S-Vax-loaded autologous dendritic cell therapyCOVID19 s-vax loaded autologous dendritic cellCOVID-19 s-vax loaded autologous dendritic cellCOVID 19 s-vax loaded autologous dendritic cellCOVID19 s-vax loaded autologous dendritic cell therapyCOVID-19 s-vax loaded autologous dendritic cell therapyCOVID 19 s-vax loaded autologous dendritic cell therapyS-Vax-loaded autologous dendritic cell vaccine

Targets

γδ TCR (T-cell receptor)SARS-CoV-2 spike

Beyond the preview

Go deeper on COVID-19 S-Vax-loaded autologous dendritic cell injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 S-Vax-loaded autologous dendritic cell injection.

Explore the full profile